Argenx & their Vyvgart product is very targeted at the moment
CSL Ig products are varied & used for treating many varied conditions
Vyvgart is not a direct replacement for Ig products & is not approved to treat a wide range of conditions
Argenx has succeeded in developing a new treatment...
VYVGART is the first FDA-approved treatment of its kind for adults with anti-AChR antibody positive generalized myasthenia gravis (gMG).
Vyvgart was administered along with existing treatments - at this stage it is NOT a complete replacement & has not been approved for use in treating any other autoimmune based disorders
Amazing research & development by Argenx & doesn't seem to be of much concern to CSL Ig at this stage
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)